Opinion|Videos|December 23, 2024
Long-Term Cognitive Effects of Cladribine: SDMT Score Changes in the CLARIFY-MS Extension Study
Author(s)Gabriel Pardo, MD, FAAN, Martin Belkin, DO
Key Takeaways
- Fingolimod, siponimod, and natalizumab can penetrate the blood-brain barrier, potentially impacting brain health directly.
- The impact of DMTs on cognitive health is under investigation, with some evidence suggesting benefits in slowing cognitive decline.
Panelists discuss how the CLARIFY-MS extension study revealed stable cognitive function 4 years post cladribine, highlighting the potential of early treatment to preserve cognitive capabilities in multiple sclerosis (MS) patients. Cognitive assessments remain crucial for monitoring disease progression and tailoring patient management.
Advertisement
Video content above is prompted by the following:
- Cognition data was examined in the CLARIFY-MS extension study in patients 4 years after initial dose of cladribine. Please discuss changes in Symbol Digit Modalities Test (SDMT) scores over time and what these results mean for the cognitive function of the patient.
- What are your impressions of long-term cognition data with other high-efficacy therapies?
- How do you utilize cognitive data in your practice?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Cladribine More Effective Than S1P Receptor Modulators in Treating Relapsing-Remitting MS, Study Shows
2
FDA Adds Boxed Warning, Narrows Indication for DMD Gene Therapy
3
BBP-418 Success in LGMD, Alixorexton Improves Narcolepsy Symptoms, Fenebrutinib Meets Phase 3 End Points
4
Using Machine Learning for Risk Prediction in Multiple Sclerosis Following DMT Discontinuation: Marisa McGinley, DO
5
